(Q77569194)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Low-density lipoproteins and risk for coronary artery disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

main subject

coronary artery disease

1 reference

C M Ballantyne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 November 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

9A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

3Q-12Q

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol.

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Cholesterol reduction yields clinical benefit. A new look at old data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Lipid-lowering interventions in angiographic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Cost of prevention. The case of lipid lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Statin trials and goals of cholesterol-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Reductase inhibitor monotherapy and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Range of serum cholesterol values in the population developing coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Fluvastatin with and without niacin for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

Effects of lipid lowering therapy on progression of coronary and carotid artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900769-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(98)00769-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9819098%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference